Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05425940 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer

Study acronym: STELLAR-303
StatusActive, Not Recruiting
PhasePhase 3
SponsorExelixis
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date changed from estimate of May 2026 to Jun 16, 2026 Completion date: Jan 2027 to Jan 31, 2027v29 Show 1 more changeShow less
    • Completion date: Jan 2027 to Jan 31, 2027
  2. Primary completion date: Aug 2025 to May 2026 Primary endpoints: 1 to 2 · Enrollment target: estimated 874 to confirmed 901 · Completion date: Feb 2026 to Jan 2027 · 3 morev28 Show 6 more changesShow less
    • Primary endpoints: 1 to 2
    • Enrollment target: estimated 874 to confirmed 901
    • Completion date: Feb 2026 to Jan 2027
    • Eligibility criteria expanded, about 20 words
    • Secondary endpoints: 1 to 7
    • Study title revised

    See this version in full on ClinicalTrials.gov ↗

  3. Trial status: Recruiting to Active, Not Recruiting Site details revised at 133 of 133 sitesv27 Show 1 more changeShow less
    • Site details revised at 133 of 133 sites
  4. Study sites: 132 to 133v26
  5. Study sites: 128 to 132v25
Show 23 earlier versionsHide 23 earlier versions
  1. Primary endpoints: 2 to 1 Enrollment target: 600 to 874 · Study sites: 115 to 128 · Eligibility criteria expanded, about 170 words · 1 morev24 Show 4 more changesShow less
    • Enrollment target: 600 to 874
    • Study sites: 115 to 128
    • Eligibility criteria expanded, about 170 words
    • Secondary endpoints expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  2. Study sites: 113 to 115v23
  3. Study sites: 109 to 113v22
  4. Study sites: 104 to 109v21
  5. Study sites: 100 to 104v20
  6. Study sites: 96 to 100v19
  7. Study sites: 84 to 96v18
  8. Study sites: 77 to 84v17
  9. Study sites: 71 to 77v16
  10. Study sites: 64 to 71v15
  11. Primary endpoints: 1 to 2 Study sites: 54 to 64v14 Show 1 more changeShow less
    • Study sites: 54 to 64

    See this version in full on ClinicalTrials.gov ↗

  12. Study sites: 51 to 54v13
  13. Study sites: 46 to 51v12
  14. Study sites: 38 to 46v11
  15. Study sites: 16 to 38v10
  16. Study sites: 12 to 16v9
  17. Study sites: 8 to 12v8
  18. Study sites: 7 to 8v7
  19. Study sites: 5 to 7v6
  20. Start date changed from estimate of Aug 2022 to Sep 7, 2022v5
  21. Study sites: 1 to 5v4
  22. Start date: Jun 2022 to Aug 2022v3
  23. Eligibility criteria expanded, about 2 words Collaborators shortened, about 3 wordsv2 Show 1 more changeShow less
    • Collaborators shortened, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Exelixis
25 trials monitored
See 2 trials at risk
Colorectal Cancer
2,920 trials monitored
See 132 trials at risk
The primary purpose of this study is to evaluate XL092 + atezolizumab versus regorafenib in participants with microsatellite stable/microsatellite instability low (MSS/MSI-low) metastatic colorectal cancer (mCRC) who have progressed during, after or are intolerant to standard-of-care (SOC) therapy.
Trial Details
NCT Number NCT05425940
Lead Sponsor Exelixis
Conditions Colorectal Cancer
Enrollment 901 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov